275 related articles for article (PubMed ID: 28961381)
1. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy.
Dahbour S; Jamali F; Alhattab D; Al-Radaideh A; Ababneh O; Al-Ryalat N; Al-Bdour M; Hourani B; Msallam M; Rasheed M; Huneiti A; Bahou Y; Tarawneh E; Awidi A
CNS Neurosci Ther; 2017 Nov; 23(11):866-874. PubMed ID: 28961381
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
[TBL] [Abstract][Full Text] [Related]
3. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
Harris VK; Vyshkina T; Sadiq SA
Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.
Harris VK; Stark J; Vyshkina T; Blackshear L; Joo G; Stefanova V; Sara G; Sadiq SA
EBioMedicine; 2018 Mar; 29():23-30. PubMed ID: 29449193
[TBL] [Abstract][Full Text] [Related]
5. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
Trials; 2019 May; 20(1):263. PubMed ID: 31072380
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
[TBL] [Abstract][Full Text] [Related]
8. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis.
Riordan NH; Morales I; Fernández G; Allen N; Fearnot NE; Leckrone ME; Markovich DJ; Mansfield D; Avila D; Patel AN; Kesari S; Paz Rodriguez J
J Transl Med; 2018 Mar; 16(1):57. PubMed ID: 29523171
[TBL] [Abstract][Full Text] [Related]
9. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA; Imrey PB; Planchon SM; Bermel RA; Fisher E; Fox RJ; Bar-Or A; Sharp SL; Skaramagas TT; Jagodnik P; Karafa M; Morrison S; Reese Koc J; Gerson SL; Lazarus HM
Mult Scler; 2018 Apr; 24(4):501-511. PubMed ID: 28381130
[TBL] [Abstract][Full Text] [Related]
10. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.
Llufriu S; Sepúlveda M; Blanco Y; Marín P; Moreno B; Berenguer J; Gabilondo I; Martínez-Heras E; Sola-Valls N; Arnaiz JA; Andreu EJ; Fernández B; Bullich S; Sánchez-Dalmau B; Graus F; Villoslada P; Saiz A
PLoS One; 2014; 9(12):e113936. PubMed ID: 25436769
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cell transplantation in multiple sclerosis.
Cohen JA
J Neurol Sci; 2013 Oct; 333(1-2):43-9. PubMed ID: 23294498
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA
Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390
[TBL] [Abstract][Full Text] [Related]
13. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
Connick P; Kolappan M; Crawley C; Webber DJ; Patani R; Michell AW; Du MQ; Luan SL; Altmann DR; Thompson AJ; Compston A; Scott MA; Miller DH; Chandran S
Lancet Neurol; 2012 Feb; 11(2):150-6. PubMed ID: 22236384
[TBL] [Abstract][Full Text] [Related]
14. Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation.
Chahal J; Gómez-Aristizábal A; Shestopaloff K; Bhatt S; Chaboureau A; Fazio A; Chisholm J; Weston A; Chiovitti J; Keating A; Kapoor M; Ogilvie-Harris DJ; Syed KA; Gandhi R; Mahomed NN; Marshall KW; Sussman MS; Naraghi AM; Viswanathan S
Stem Cells Transl Med; 2019 Aug; 8(8):746-757. PubMed ID: 30964245
[TBL] [Abstract][Full Text] [Related]
15. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.
Connick P; Kolappan M; Patani R; Scott MA; Crawley C; He XL; Richardson K; Barber K; Webber DJ; Wheeler-Kingshott CA; Tozer DJ; Samson RS; Thomas DL; Du MQ; Luan SL; Michell AW; Altmann DR; Thompson AJ; Miller DH; Compston A; Chandran S
Trials; 2011 Mar; 12():62. PubMed ID: 21366911
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.
Yamout B; Hourani R; Salti H; Barada W; El-Hajj T; Al-Kutoubi A; Herlopian A; Baz EK; Mahfouz R; Khalil-Hamdan R; Kreidieh NM; El-Sabban M; Bazarbachi A
J Neuroimmunol; 2010 Oct; 227(1-2):185-9. PubMed ID: 20728948
[TBL] [Abstract][Full Text] [Related]
17. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study.
Mohyeddin Bonab M; Yazdanbakhsh S; Lotfi J; Alimoghaddom K; Talebian F; Hooshmand F; Ghavamzadeh A; Nikbin B
Iran J Immunol; 2007 Mar; 4(1):50-7. PubMed ID: 17652844
[TBL] [Abstract][Full Text] [Related]
18. Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis.
Vaheb S; Afshin S; Ghoshouni H; Ghaffary EM; Farzan M; Shaygannejad V; Thapa S; Zabeti A; Mirmosayyeb O
Mult Scler Relat Disord; 2024 Jul; 87():105681. PubMed ID: 38838423
[TBL] [Abstract][Full Text] [Related]
19. Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up.
Blanco JF; Villarón EM; Pescador D; da Casa C; Gómez V; Redondo AM; López-Villar O; López-Parra M; Muntión S; Sánchez-Guijo F
Stem Cell Res Ther; 2019 Feb; 10(1):63. PubMed ID: 30795797
[TBL] [Abstract][Full Text] [Related]
20. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy.
Centeno C; Markle J; Dodson E; Stemper I; Williams CJ; Hyzy M; Ichim T; Freeman M
J Transl Med; 2017 Sep; 15(1):197. PubMed ID: 28938891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
